Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Retatrutide (development code LY3437943) is an investigational once-weekly injectable weight loss medication developed by Eli Lilly and Company the same pharmaceutical company behind Mounjaro (tirzepatide) and the oral GLP-1 pill orforglipron (Foundayo)
This article explores the difference between these two powerhouse molecules, examining the efficacy data, safety profiles, and, most importantly, the clinical implications for patients seeking advanced, comprehensive metabolic health in 2025 and beyond
Longevity Medical Institute uses that diagnostics-first model to combine advanced lab panels, personalized hormone replacement therapy, physician-guided peptide therapy, lifestyle coaching, and ongoing monitoring
By paying attention to these symptoms, you may be able to better recognize how your body reacts to the medication
In clinical trials, tirzepatide (Zepbound) has produced the largest average weight loss of any approved Canadian GLP-1
US$ 21.85
US$ 24.96
US$ 20.17
US$ 22.93
